We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BioXcel Therapeutics Inc | NASDAQ:BTAI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.39% | 2.57 | 0.97 | 3.92 | 2.6701 | 2.56 | 2.60 | 147,562 | 05:00:11 |
From May 2021 to May 2024
Presentation Details:
Event: Jefferies Virtual Healthcare ConferenceDate: Wednesday, June 2, 2021Time: 10:30 AM ET
Event: Goldman Sachs 42nd Annual Global Healthcare ConferenceDate: Wednesday, June 9, 2021Time: 4:40 PM ET
Event: BofA Securities Napa Biopharma ConferenceDate: Monday, June 14, 2021Time: 11:30 AM ET
Live webcasts of the fireside chats will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conferences, the webcasts will be archived on the Company’s website for at least 30 days.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel’s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com
Investor Relations:Mary ColemanBioXcel Therapeutics, VP of Investment RelationsMColeman@bioxceltherapeutics.com 1.475.238.6837
John GrazianoSolebury Troutjgraziano@soleburytrout.com 1.646.378.2942
Media:
Julia DeutschSolebury Troutjdeutsch@soleburytrout.com 1.646.378.2967
1 Year BioXcel Therapeutics Chart |
1 Month BioXcel Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
